International Journal of Clinical Research

Objective: To study and analyze the clinical efficacy and safety of HAIC combined with lenvatinib and PD1 monoclonal antibody based on FOLFOX regimen in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus. Methods Taking the period from September 1, 2020 to November 30, 2021 as the research period, 56 patients with hepatocellular carcinoma combined with portal vein tumor thrombus received in our hospital were selected as the research objects and randomly divided into two groups There were 28 patients in the control group and the experimental group, respectively. The patients in the control group were treated with lenvatinib and tislelizumab, and the experimental group was treated with HAIC combined therapy based on the FOLFOX regimen under this premise. After treatment, the clinical efficacy of the two groups of patients was compared. Results The total effective rate of clinical treatment in the experimental group was higher than that in the control group, and the difference was statistically significant (P<0.05), and the incidence of complications was not significantly increased. Conclusion The FOLFOX-based regimen of HAIC combined with lenvatinib and PD1 monoclonal antibody has good clinical efficacy in the treatment of patients with advanced hepatocellular carcinoma complicated with portal vein tumor thrombus, and does not increase the incidence of complications.

FOLFOX regimen; HAIC combined with lenvatinib and tislelizumab therapy; advanced hepatocellular carcinoma with portal vein tumor thrombus